Functional loss in early age-related maculopathy: The ischaemia postreceptoral hypothesis

Eye

Volumn 21, Issue 6, 2007, Pages 689-696

  Feigl, B ^a   Brown, B ^a   Lovie Kitchin, J ^a   Swann, P ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOL; VASCULOTROPIN;

ARTICLE; BLINDNESS; BRUCH MEMBRANE; DRUSEN; ELECTROPHYSIOLOGY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; INFLAMMATION; METABOLIC ACTIVATION; PHOTORECEPTOR; RETINA BLOOD FLOW; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA PIGMENT DEGENERATION; VISUAL CORTEX; VISUAL IMPAIRMENT;

EID: 34250325516     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702389     Document Type: Article

References (111)

1. Fine S. Age-related macular degeneration 1969-2004: A personal perspective. Am J Ophthalmol 2005; 139: 405-420.
2. Bird A. Age-related macular disease: An ongoing challenge. Clin Exp Ophthalmol 2003; 31: 461-463.
3. Bird A. Towards an understanding of age-related macular disease. Eye 2003; 17: 457-466.
4. Pauleikhoff D. Neovascular age-related macular degeneration. Natural history and treatment outcomes. Retina 2005; 25: 1062-1084.
5. International ABCR Screening Consortium. Statistically significant association of sequence variants in ABCR gene with age-related macular degeneration. AM J Hum Genet 2000; 67: 487-491.
6. Allikmets R, Shroyer N, Seddon J, Levis R, Bernstein P, Peiffer A et al. Mutation of the Stargardt disease gene (ABCR) in age-related macular degeneration. Science 1997; 277: 1805-1807.
7. Hageman G, Anderson D, Johnson L, Hancox L, Taiber A, Hardisty L et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-7232.
8. Gass J. Pathogenesis of disciform macular detachment of the neuro-epithelium. 3. Senile disciform macular degeneration. Am J Ophthalmol 1967; 63: 617-644.
9. Sarks J, Sarks S, Killingworth M. Evolution of soft drusen in age-related macular degeneration. Eye 1994; 8: 269-283.
10. Guymer R, Luthert P, Bird A. Changes in Bruch's membrane and related structures with age. Prog Ret Eye Res 1998; 18: 59-90.
11. Bird A. Pathogenesis of retinal pigment epithelial detachment in the elderly; the relevance of Bruch's membrane change. Eye 1991; 5 1-12.
12. Boulton M, Dayhaw-Barker P. The role of the retinal pigment epithelium: topographical variations and ageing changes. Eye 2001; 15: 384-389.
13. Holz F, Pauleikhoff D, Klein R, Bird A. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 2004; 137: 504-510.
14. Bressler N, Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119: 198-207.
15. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularisation in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials - TAP report no. 5. Arch Ophthalmol 2002; 120: 1307-1314.
16. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200-1209.
17. Age- Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high dose supplementation with vitamins C and E, betacarotene and zinc for age-related macular degeneration and vision loss - AREDS report no 8. Arch Ophthalmol 2001; 119: 1417-1436.
18. Gragoudas E, Adamis A, Cunningham E, Feinsod M, Guyer D, for the VEGF Inhibition Study in Ocular Neovascularisation Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
19. Bird A, Bressler N, Bressler S, Chisholm I, Coscas G, Davis M et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995; 39: 367-374.
20. Elsner A, Burns S. Cone photopigment in older subjects: Decreased optical density in early age-related macular degeneration. J Opt Soc Am A 2002; 19: 215-222.
21. Phipps J, Guymer R, Vingrys A. Loss of cone function in age-related maculopathy. Invest Ophthalmol Vis Sci 2003; 44: 2277-2283.
22. Smith V, Pokorny J, Diddie K. Color matching and Stiles-Crawford effect in observers with early age-related macular degeneration. J Opt Soc Am A 1988; 5: 2113-2121.
23. Zele AJ, O'Loughlin RK, Guymer RH, Vingrys AJ. Disclosing disease mechanism with a spatio-temporal summation paradigm. Graefe's Arch Clin Exp Ophthalmol 2006; 244: 425-432.
24. Mayer M, Spiegler S, Ward B, Glucs A, Kim C. Mid-frequency loss of foveal flicker sensitivity in early stages of age-related maculopathy. Invest Ophthalmol Vis Sci 1992; 33: 3136-3142.
25. Phipps JA, Dang TM, Vingrys AJ, Guymer RH. Flicker perimetry losses in age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45: 3355-3360.
26. Pauleikhoff D. Drusen in Bruch's membrane. Their significance for the pathogenesis and therapy of age-associated macular degeneration. Ophthalmology 1992; 89: 363-386.
27. Friedman E, Krupsky S, Lane A, Oak S, Friedman E, Egan K et al. Ocular blood flow velocity in age-related macular degeneration. Ophthalmology 1995; 102: 640-646.
28. Chen J, Fitzke F, Pauleikhoff D, Bird A. Functional loss in age-related Bruch's membrane change with choroidal perfusion defect. Invest Ophthalmol Vis Sci 1992; 33: 334-340.
29. Grunwald J, Hariprasad S, DuPont J, Maguire M, Fine S, Brucker A et al. Foveal choroidal blood flow in age-related macular degeneration (AMD). Invest Ophthalmol Vis Sci 1998; 39: 385-390.
30. Pauleikhoff D, Chen J, Chisholm I, Bird A. Choroidal perfusion abnormality with age-related Bruch's membrane change. Am J Ophthalmol 1990; 109: 211-217.
31. Ciulla T, Harris A, Chung H. Color Doppler imaging discloses reduced ocular blood flow velocities in non-exudative age-related macular degeneration. Am J Ophthalmol 1999; 128: 75-80.
32. Lovie-Kitchin J, Feigl B. Assessment of age-related maculopathy using subjective vision tests. Clin Exp Optom 2005; 88: 292-303.
33. Feigl B, Lovie-Kitchin J, Brown B. Objective functional assessment of age-related maculopathy: A special application for the multifocal electroretinogram. Clin Exp Optom 2005; 88: 304-312.
34. Eisner A, Klein M, Zilis J, Watkins M. Visual function and the subsequent development of exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 1992; 33: 3091-3102.
35. Collins M. Pre-age-related maculopathy and the desaturated D-15 colour vision test. Clin Exp Opt 1986; 69: 223-227.
36. Owsley C, Jackson G, White M, Edwards D. Delays in rod-mediated dark-adaptation in early age-related maculopathy. Ophthalmology 2001; 108: 1196-1202.
37. Owsley C, Jackson G, Cideciyan A, Huang Y, Fine S, Ho A et al. Psychophysical evidence for rod vulnerability in age-related macular degeneration. Invest Ophthalmol Vis Sci 2000; 41: 267-273.
38. Feigl B, Brown B, Lovie-Kitchin J, Swann P. Cone- and rod-mediated mfERG in early age-related maculopathy. Eye 2005; 19: 431-441.
39. Feigl B, Brown B, Lovie-Kitchin J, Swann P. Monitoring retinal function in early age-related maculopathy: Visual performance after one year. Eye 2005; 19: 1169-1177.
40. Chen C, Wu L, Wu D, Huang S, Wen F, Luo G et al. The local cone and rod system function in early age-related macular degeneration. Doc Ophthalmol 2004; 109: 1-8.
41. Steinmetz R, Haimovici R, Jubb C, Fitzke F, Bird A. Symptomatic abnormalities of dark adaptation in patients with age-related Bruch's membrane change. Br J Ophthalmol 1993; 77: 549-554.
42. Scholl H, Bellmann C, Dandekar S, Bird A, Fitzke F. Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. Invest Ophthalmol Vis Sci 2004; 45: 574-583.
43. Curcio C. Photoreceptor topography in aging and age-related maculopathy. Eye 2001; 15: 376-383.
44. Jackson GR, Owsley C, Curcio CA. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev 2002; 1: 381-396.
45. Curcio C, Owsley C, Jackson G. Spare the rods, save the cones in aging and age-related maculopathy. Invest Ophthalmol Vis Sci 2000; 41 2015-2018.
46. Collins M, Brown B. Glare recovery and its relation to other clinical findings in age related maculopathy. Clin Vis Sci 1989; 4: 155-163.
47. Cheng A, Vingrys A. Visual losses in early age-related maculopathy. Optom Vis Sci 1993; 70: 89-96.
48. Eisner A, Stoumbos V, Klein M, Fleming A. Relation between fundus appearance and function. Eyes whose fellow eye has exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 1991; 32: 8-20.
49. Vingerling J, Dielemans I, Bots M, Hofman A, Grobbee D, de Jong P. Age-related macular degeneration is associated with atherosclerosis. The Rotterdam Study. Am J Epidemiol 1995; 142: 404-409.
50. Grunwald J, Metelitsina T, DuPont J, Ying G-S, Maguire M. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46: 1033-1038.
51. Pauleikhoff D, Spital G, Radermacher M, Brumm G, Lommatzsch A, Bird A. A fluorescein and indocyanine green angiographic study of choriocapillaris in age-related macular disease. Arch Ophthalmol 1999; 117: 1353-1358.
52. Linsenmeier R, Padnick-Silver L. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. Invest Ophthalmol Vis Sci 2000; 41: 3117-3123.
53. Schlingemann R. Role of growth factors and the wound healing response in age-related macular degeneration. Graefe's Arch Clin Exp Ophthalmol 2004; 242: 91-101.
54. Robbins S, Cotran R. Robbins and Cotran pathologic basis of disease. In: Kumar V, Abbas AK, Fausto N (eds). Robbins and Cotran Pathologic Basis of Disease, 7th ed. Saunders: Philadelphia, 2004.
55. Witmer A, Vrensen G, Van Noorden C, Schlingemann R. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Ret Eye Res 2003; 22: 1-29.
56. Sakamoto T, Sakamoto H, Murphy T, Spee C, Soriano D, Ishibashi T et al. Vessel formation by choroidal endothelial cells in vitro is modulated by retinal pigment epithelium cells. Arch Ophthalmol 1995; 113: 512-520.
57. Ramrattan R, van der Schaft T, Mooy C, de Bruijin W, Mulder P, de Jong P. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 1994; 35: 2857-2864.
58. Zarbin M. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004; 122: 598-641.
59. Sarks S, Sarks J. Age-related maculopathy: Nonneovascular age-related macular degeneration and the evolution of geographic atrophy. In: Ryan SJ, Schachat AP (eds). Retina. 3rd edn. Medical Retina,vol.2 Mosby: Philadelphia, 2001, pp 1064-1099.
60. Hageman G, Luthert P, Victor Chong N, Johnson L, Anderson D, Mullins R. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retinal Eye Res 2001; 20: 705-732.
61. Pauleikhoff D, Harper C, Marshall J, Bird A. Ageing changes in Bruch's membrane. A histochemical and morphological study. Ophthalmology 1990; 97: 171-178.
62. Holz F, Sheraidah G, Pauleikhoff D, AC B. Analysis of lipid deposits extracted from human macular and peripheral Bruch's membrane. Arch Ophthalmol 1994; 112: 402-406.
63. Arden G, Wolf J. Differential effects of light and alcohol on the electro-oculographic responses of patients with age-related macular disease. Invest Ophthalmol Vis Sci 2003; 44: 3226-3232.
64. Bui BV, Vingrys AJ, Kalloniatis M. Correlating retinal function and amino acid immunocytochemistry following post-mortem ischemia. Exp Eye Res 2003; 77: 125-136.
65. Yu D-Y, Cringle S. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Ret Eye Res 2001; 20: 175-208.
66. Cringle S, Yu D-Y, Yu P, Su E-N. Intraretinal oxygen consumption in the rat in vivo. Invest Ophthalmol Vis Sci 2002; 43: 1922-1927.
67. Smith VC, Ernest T, Pokorny J. Effect of hypoxia on FM 100-hue test performance. Mod Probl Ophthalmol 1976; 17: 248-256.
68. Arden G, Wolf J, Tsang Y. Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis. Vision Res 1997; 38: 1723-1729.
69. Greenstein V, Hood D, Ritch R, Steinberg R, Carr RS. Blue) cone pathway vulnerability in retinitis pigmentosa, diabetes and glaucoma. Invest Ophthalmol Vis Sci 1989; 30: 1732-1737.
70. Greenstein V, Hood D, Carr R. S cone pathway vulnerability: Differential effects of retinitis pigmentosa and diabetes. Invest Ophthalmol Vis Sci 1987; 28: 113.
71. Arden G, Sidman R, Arap W, Schlingemann R. Spare the rod and spoil the eye. Br J Ophthalmol 2005; 89: 764-769.
72. McLeod DS, Lutty GA. High-resolution histologic analysis of the human choroidal vasculature. Invest Ophthalmol Vis Sci 1994; 35: 3799-3811.
73. Sarks J, Sarks S, Killingworth M. Evolution of geographic atrophy of the retinal pigment epithelium. Eye 1988; 2: 552-577.
74. Hayreh S, Gartner S. In vivo choroidal circulation and its watershed zones. Eye 1990; 4: 273-289.
75. Linsenmeier R. Electrophysiological consequences of retinal hypoxia. Graefe's Arch Clin Exp Ophthalmol 1990; 228: 143-150.
76. Linsenmeier R, Braun R. Oxygen distribution and consumption in the cat retina during normoxia and hypoxia. J Gen Physiol 1992; 99: 177-197.
77. Friedman E, Chandra S. Choroidal blood flow. III Effects of oxygen and carbon dioxide. Arch Ophthalmol 1972; 87: 70-71.
78. 2 on relative retinal blood flow in monkeys. Invest Ophthalmol Vis Sci 1975; 14: 342-352.
79. Medeiros N, Curcio A. Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42: 795-803.
80. Grozdanic S, Sakaguchi D, Kwon Y, Kardon R, Sonea I. Functional characterization of retina and optic nerve after acute ocular ischemia in rats. Invest Ophthalmol Vis Sci 2003; 44: 2597-2605.
81. Johnson A, Lutty G, McLeod D, Otsuji T, Flower R, Sandagar G et al. Ocular structure and function in an aged monkey with spontaneous diabetes mellitus. Exp Eye Res 2005; 80: 37-42.
82. Coleman K, Fitzgerald D, Eustace P, Bouchier-Hayes D. Electroretinography, retinal ischemia and carotid artery disease. Eur J Vasc Surg 1990; 4: 13-18.
83. Block F, Schwarz M. The b-wave of the electroretinogram as an index of retinal ischemia. Gen Pharmacol 1998; 30: 281-287.
84. Han Y, Bearse MJ, Schneck M, Barez S, Jacobson C, Adams A. Multifocal electroretinogram delays predict sites of subsequent diabetic retinopathy. Invest Ophthalmol Vis Sci 2004; 45: 948-954.
85. Sandberg M, Miller S, Gaudio A. Foveal cone ERGs in fellow eyes of patients with unilateral neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 1993; 34: 3477-3480.
86. Hood D, Wladis E, Shady S, Holopigian K, Li J, Seiple W. Multifocal rod electroretinograms. Invest Ophthalmol Vis Sci 1998; 39: 1152-1161.
87. Han Y, Adams A, Bearse M, Schneck M. Multifocal electroretinogram and short-wavelength automated perimetry measures in diabetic eyes with little or no retinopathy. Arch Ophthalmol 2004; 122: 1809-1815.
88. Schneck M, Fortune B, Switkes E, Crognale M, Adams A. Acute effects of blood glucose on chromatic visually evoked potentials in persons with diabetes and in normal persons. Invest Ophthalmol Vis Sci 1997; 38: 800-810.
89. Feigl B, Brown B, Lovie-Kitchin J, Swann P. Cone-mediated multifocal electroretinogram in early age-related maculopathy and its relationships with subjective macular function tests. Curr Eye Res 2004; 29 327-336.
90. Brown B, Garner L. Effects of luminance on contrast sensitivity in senile macular degeneration. Am J Optom Physiol Opt 1983; 60 788-793.
91. Brown B, Lovie-Kitchin J. Contrast sensitivity in central and paracentral retina in age-related maculopathy. Clin Exp Opt 1987; 70: 145-148.
92. Chen C, Wu L, Jiang F, Liang J, Wu D. Scotopic sensitivity of central retina in early age-related macular degeneration. Yan Ke Xue Bao 2003; 19: 15-19.
93. Blaauweegers H, Holtkamp G, Rutten H, Witmer AN, Koolwijk P, Patanen A et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localisation of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a paracrine relation. Am J Pathol 1999; 155: 412-428.
94. Lip P, Blann A, Hope-Ross M, Gibson J, Lip G. Age-related macular degeneration is associated with increased vascular growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001; 108: 705-710.
95. Kliffen M, Sharma H, Mooy C, Kerkvliet S, de Jong P. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154-162.
96. Amin R, Puklin J, Frank R. Growth factor localisation in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994; 35: 3178-3188.
97. Gonzales C, VEGF Inhibition Study In Ocular Neovascularisation (V.I.S.I.O.N) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina 2005; 25: 815-827.
98. Avery R, Pieramici D, Rabena M, Castellarin A, Nasir M, Guist M. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-372.
99. Heier J, AN A, Pavan P, Leff S, Rosenfeld P, Ciulla T et al. Ranibizumab for treatment of neovascular age-related macular degeneration a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006; 2006 February 13 [E-pub ahead of print].
100. Klein R, Zeiss C, Chew E, Tsai J-Y, Sackler R, Haynes C et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308: 385-389.
101. Zareparsi S, Branham K, Li M, Shah S, Klein R, Ott J et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 2005; 77: 149-153.
102. Bok D. Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci 2005; 102 7053-7054.
103. Ezzati M, Henley S, Thun M, Lopez A. Role of smoking in global and regional cardiovascular mortality. Circulation 2005; 112: 489-497.
104. Hankey G. Preventable stroke and stroke prevention. J Thromb Haemost 2005; 3: 1638-1645.
105. Mitchell P, Wang J, Smith W, Leeder S. Smoking and the 5-years incidence of age-related maculopathy: The Blue Mountain Eye Study. Arch Ophthalmol 2002; 120: 1357-1363.
106. Haines J, Schnetz-Boutaud N, Schmidt S, Scott W, Agarwal A, Postel E et al. Functional candidate genes in age-related macular degeneration: Significant association with VEGF, VLDLR, andLRP6. Invest Ophthalmol Vis Sci 2006; 47: 329-335.
107. Jackson G, Owsley C, Curcio C. Photoreceptor degeneration and dysfunction in aging and age-related maculopathy. Ageing Res Rev 2002; 1: 381-396.
108. Haimovici R, Owens S, Fitzke F, Bird A. Dark adaptation in age-related macular degeneration: Relationship to the fellow eye. Graefe's Arch Clin Exp Ophthalmol 2002; 240: 90-95.
109. Nguyen Q, Shah S, Van Anden E, Sung J, Vitale S, Campochiaro P. Supplemental oxygen improves diabetic macular edema: A pilot study. Invest Ophthalmol Vis Sci 2004; 45: 617-624.
110. Riva Sanseverino E, Meduri R, Pizzino A, Prantera M, Martini E. Effects of oxygen-ozone therapy on age-related degenerative retinal maculopathy. Panminerva Med 1990; 32: 77-84.
111. Teichmann K. Treatment of macular degeneration, according to Bangerter. Eur Med Res 1997; 2: 445-454.